About Careers MedBlog Contact us

Costly Cancer Treatments Questioned by US Docs

by Rajashri on June 30, 2009 at 9:42 PM
Font : A-A+

 Costly Cancer Treatments Questioned by US Docs

The wisdom and utility of treating terminally ill cancer patients with expensive treatments that only extend their lives by weeks has been questioned by two National Institutes of Health (NIH) practitioners.

In a commentary published Monday in the Journal of the National Cancer Institute, the pair wrote that the use of extremely expensive treatments that barely extend patients' lives "is a serious ethical dilemma in the US that needs to be addressed by the oncology community."


Specifically, the authors ask, "Is an additional 1.7 months (the additional overall survival for colorectal cancer patients treated with cetuximab) a benefit regardless of costs and side effects?"

Cetuximab, which is made by the American pharmaceutical company Merck, is also prescribed for advanced cases of lung cancer.

According to study authors Tito Fojo, an oncologist at the National Cancer Institute, and Christine Grady, an NIH bioethicist, an 18-week course of cetuximab for a lung cancer patient would cost about 80,000 dollars and extend the patient's life by an average of 1.2 months.

Using the drug to extend a patient's life by a year could cost 800,000 dollars, the authors wrote.

It would cost 440 billion dollars annually, a figure 100 times more than the National Cancer Institute's budget, to extend by one year the lives of the 550,000 Americans who die of cancer each year.

The authors recommend that studies geared towards treatments that will extend patients' lives by two months or less only consider interventions that will cost 20,000 dollars or less.

"We cannot ignore the cumulative costs of the tests and treatments we recommend and prescribe," the commentary said.

"As the agents of change, professional societies, including their academic and practicing oncologist members, must lead the way. The time to start is now," the authors wrote.

The research comes amid considerable debate over US "baby boomers" -- born in the aftermath of World War II and the largest US generation -- tens of millions of whom are now reaching retirement and whose end-of-life health care costs will have a substantial impact on the US economy.

The commentary was published amid new efforts by President Barack Obama and his allies to reform the US health care system, which is expensive and leaves more than 40 million people uncovered.

Source: AFP


Recommended Reading

Latest Cancer News

 Myelofibrosis: New Drugs to Revolutionize Treatment
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
 Blood Vessels Can Kill Cancer Cells and Stop Breast Cancer Spread
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
 Weed Killer Agent Orange May Increase the Risk of Blood Cancer Among Veterans
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Two Years: Optimal Duration of Immunotherapy in Advanced Lung Cancer
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
Hope for Lethal Brain Tumors: Targeted Therapy Delays Glioma Progression
A ray of hope for glioma patients as targeted therapy boosts treatment duration.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Costly Cancer Treatments Questioned by US Docs Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests